ICI-192605
ICI-192605 is a chemical compound that has been studied for its potential pharmacological effects, particularly as a selective antagonist of the 5-HT2 receptor. This compound was developed by Imperial Chemical Industries (ICI), a company known for its research in pharmaceuticals and chemicals.
Pharmacology[edit | edit source]
ICI-192605 is primarily known for its action as a selective antagonist of the 5-HT2 receptor, which is a subtype of the serotonin receptor. The 5-HT2 receptor is involved in various neurological processes, including mood regulation, perception, and cognition. By blocking this receptor, ICI-192605 can potentially alter these processes, making it a compound of interest in the study of psychiatric and neurological disorders.
Mechanism of Action[edit | edit source]
The mechanism of action of ICI-192605 involves its binding to the 5-HT2 receptor, preventing serotonin from activating this receptor. This antagonistic action can lead to a decrease in the downstream effects typically mediated by serotonin, such as neurotransmitter release and neuronal excitability.
Potential Applications[edit | edit source]
Research into ICI-192605 has suggested potential applications in the treatment of disorders such as schizophrenia, depression, and anxiety disorders. By modulating the serotonergic system, ICI-192605 could help in managing symptoms associated with these conditions.
Chemical Properties[edit | edit source]
ICI-192605 is characterized by its specific chemical structure, which allows it to selectively bind to the 5-HT2 receptor. The compound's chemical formula and molar mass are important for understanding its pharmacokinetics and pharmacodynamics.
Research and Development[edit | edit source]
The development of ICI-192605 was part of a broader effort to understand the role of serotonin receptors in the brain and to develop drugs that can selectively target these receptors. While ICI-192605 itself may not be used clinically, it has contributed to the understanding of serotonin receptor pharmacology and the development of other therapeutic agents.
Also see[edit | edit source]
- 5-HT2 receptor
- Serotonin receptor
- Antagonist (pharmacology)
- Schizophrenia
- Depression
- Anxiety disorders
Template:Receptor pharmacology
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
